About Aspire Biopharma
Aspire Biopharma is a company based in United States founded in 2021. Aspire Biopharma has completed 1 acquisition, including Dura-Shiloh. Aspire Biopharma offers products and services including Sublingual Aspirin and Soluble Formulations. Aspire Biopharma operates in a competitive market with competitors including Flexion Therapeutics, Cara Therapeutics, Eliem Therapeutics, Ethypharm and Zogenix, among others.
- Headquarter Puerto Rico
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Aspire Biopharma Inc.
-
Annual Revenue
Not available
-
Net Profit
-$12.54 M (USD)-380.85as on Dec 31, 2024
-
EBITDA
-$3.09 M (USD)-130.47as on Dec 31, 2024
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
Not available
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Aspire Biopharma
Aspire Biopharma is a publicly listed company on the NASDAQ with ticker symbol ASBP in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Aspire Biopharma
Aspire Biopharma offers a comprehensive portfolio of products and services, including Sublingual Aspirin and Soluble Formulations.
Fast-acting aspirin for pain relief via sublingual absorption.
Innovative formulations for instant drug absorption and efficacy.
Funding Insights of Aspire Biopharma
Investments & Acquisitions by Aspire Biopharma
Aspire Biopharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Dura-Shiloh.
Investment portfolio details for Aspire Biopharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Manufactures automotive parts for electrification, safety, and performance globally.
|
Locked | Locked | 1914 | Locked |
Complete acquisition details for Aspire Biopharma
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Aspire Biopharma
Detailed financials for Aspire Biopharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Aspire Biopharma Comparisons
Peer comparison for Aspire Biopharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Aspire Biopharma
Aspire Biopharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Flexion Therapeutics, Cara Therapeutics, Eliem Therapeutics, Ethypharm and Zogenix, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of therapies for the treatment of musculoskeletal disorders
|
|
| Locked | Locked | Locked |
Developer of therapeutics for pain relief and inflammatory diseases
|
|
| Locked | Locked | Locked |
Develops antibody-based treatments for autoimmune and inflammatory disorders.
|
|
| Locked | Locked | Locked |
Therapies for pain and addiction treatment are developed.
|
|
| Locked | Locked | Locked |
Drug delivery systems for CNS disorders and pain are developed.
|
|
| Locked | Locked | Locked |
Pain treatment products are developed through reformulation technologies.
|
Detailed competitors of Aspire Biopharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Aspire Biopharma
Complete news archive for Aspire Biopharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aspire Biopharma
Aspire Biopharma was founded in 2021 and raised its 1st funding round 4 years after it was founded.
Aspire Biopharma is headquartered in United States. It is registered at Puerto Rico, United States.
Kraig Higginson is the current CEO of Aspire Biopharma.
Aspire Biopharma was founded in 2021 and is based in Puerto Rico. Operations focus on the biopharmaceutical sector, where drug formulations are developed to address multiple medical conditions. Instaprin is offered as a granular or powder formulation of a soluble compound, targeted at cardiology emergencies and pain management. The company maintains a presence through its domain, aspirebiolabs.com, with Kraig Higginson serving as CEO.
Aspire Biopharma's top competitors include Flexion Therapeutics, Cara Therapeutics and Trevena.
Aspire Biopharma offers Sublingual Aspirin and Soluble Formulations.
Yes, Aspire Biopharma is publicly traded on NASDAQ under the ticker symbol ASBP.
Aspire Biopharma has made 1 acquisition, including Dura-Shiloh.
The ticker symbol of Aspire Biopharma is ASBP on NASDAQ.